Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger
Results accepted for third-party, investigator-initiated Phase 2 HALT-D study evaluating crofelemer for prevention and prophylaxis of diarrhea in breast cancer patients as a poster for
"We know shareholders and other stakeholders have been looking forward to the consummation of the merger between Dragon SPAC and Napo EU. The requirement for this complex regulatory filing with the Italian government is a new regulation enacted during COVID that applies to transactions regarding pharmaceutical assets in
Napo EU & Dragon SPAC: Short Bowel Syndrome with Intestinal Failure
Napo EU was formed with the mission to expand access to crofelemer to
"Following the consummation of the merger of Napo EU and Dragon SPAC, Napo EU will be contributing to the combined entity its exclusive license agreement with Jaguar to the crofelemer/lechlemer pipeline, and Dragon SPAC will contribute financing," Conte said.
Cancer Therapy-related Diarrhea
The investigators of the Phase 2 cancer therapy-related diarrhea (CTD) study in breast cancer patients (the HALT-D study) have been informed that the poster of the results from the study have been accepted for presentation at the San Antonio Breast Cancer Symposium in
As previously announced, the HALT-D study was sponsored by
Discussion with FDA in
Members of Jaguar's clinical development team corresponded last month with the
NP-300 is a standardized and proprietary botanical drug product that is sustainably derived from the Croton lechleri tree. This program is paired with funding from a promissory note related to the potential future sale of a possible tropical disease priority review voucher. Priority review vouchers are granted by the FDA as an incentive to develop treatments for neglected diseases and rare diseases and are transferable.
Canalevia™, Jaguar's Oral Plant-Based Prescription Drug Candidate for Treatment of Chemotherapy-induced Diarrhea in Dogs
As announced on
For more information about Jaguar, please visit https://jaguar.health. For more information about
Certain statements in this press release constitute "forward-looking statements." These include statements related to Jaguar's expectation that Canalevia will launch in